InvVax is fundamentally changing the way in which antiviral vaccines are developed. Leveraging years of technical and commercial experience in the space, the InvVax team has developed a breakthrough platform that significantly increases the vaccine hit rate against current, emerging and future variants of viruses such as Influenza, Hepatitis and SARS-COV-2. InvVax is collaborating with leading global researchers in the space to apply their best knowledge and move the technology to the next phase of commercialization & implementation. The platform can be extended to address rapid vaccine development for other viruses and future pathogens. Arthur Young, with his deep knowledge in viral genomics, Nima Shiva, with his proven track record in the biotechnology entrepreneurial space and Olga Petrauskene, with her extensive experience in viral diagnostics, create an outstanding team to bring forth a compelling platform to address the public health threat of viral infectious diseases globally.